IBDEI14F ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,18185,0)
;;=E11.620^^61^805^5
;;^UTILITY(U,$J,358.3,18185,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18185,1,3,0)
;;=3^DM Type 2 w/ Diab Dermatitis
;;^UTILITY(U,$J,358.3,18185,1,4,0)
;;=4^E11.620
;;^UTILITY(U,$J,358.3,18185,2)
;;=^5002655
;;^UTILITY(U,$J,358.3,18186,0)
;;=E11.36^^61^805^4
;;^UTILITY(U,$J,358.3,18186,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18186,1,3,0)
;;=3^DM Type 2 w/ Diab Cataract
;;^UTILITY(U,$J,358.3,18186,1,4,0)
;;=4^E11.36
;;^UTILITY(U,$J,358.3,18186,2)
;;=^5002642
;;^UTILITY(U,$J,358.3,18187,0)
;;=I10.^^61^806^1
;;^UTILITY(U,$J,358.3,18187,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18187,1,3,0)
;;=3^Essential/Primary Hypertension
;;^UTILITY(U,$J,358.3,18187,1,4,0)
;;=4^I10.
;;^UTILITY(U,$J,358.3,18187,2)
;;=^5007062
;;^UTILITY(U,$J,358.3,18188,0)
;;=I11.0^^61^806^12
;;^UTILITY(U,$J,358.3,18188,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18188,1,3,0)
;;=3^Hypertensive Heart Disease w/ Heart Failure
;;^UTILITY(U,$J,358.3,18188,1,4,0)
;;=4^I11.0
;;^UTILITY(U,$J,358.3,18188,2)
;;=^5007063
;;^UTILITY(U,$J,358.3,18189,0)
;;=I11.9^^61^806^13
;;^UTILITY(U,$J,358.3,18189,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18189,1,3,0)
;;=3^Hypertensive Heart Disease w/o Heart Failure
;;^UTILITY(U,$J,358.3,18189,1,4,0)
;;=4^I11.9
;;^UTILITY(U,$J,358.3,18189,2)
;;=^5007064
;;^UTILITY(U,$J,358.3,18190,0)
;;=I12.0^^61^806^5
;;^UTILITY(U,$J,358.3,18190,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18190,1,3,0)
;;=3^Hypertensive CKD w/ Stage 5 CKD or ESRD
;;^UTILITY(U,$J,358.3,18190,1,4,0)
;;=4^I12.0
;;^UTILITY(U,$J,358.3,18190,2)
;;=^5007065
;;^UTILITY(U,$J,358.3,18191,0)
;;=I12.9^^61^806^4
;;^UTILITY(U,$J,358.3,18191,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18191,1,3,0)
;;=3^Hypertensive CKD w/ Stage 1-4 CKD
;;^UTILITY(U,$J,358.3,18191,1,4,0)
;;=4^I12.9
;;^UTILITY(U,$J,358.3,18191,2)
;;=^5007066
;;^UTILITY(U,$J,358.3,18192,0)
;;=I13.0^^61^806^8
;;^UTILITY(U,$J,358.3,18192,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18192,1,3,0)
;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 1-4 CKD
;;^UTILITY(U,$J,358.3,18192,1,4,0)
;;=4^I13.0
;;^UTILITY(U,$J,358.3,18192,2)
;;=^5007067
;;^UTILITY(U,$J,358.3,18193,0)
;;=I13.10^^61^806^10
;;^UTILITY(U,$J,358.3,18193,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18193,1,3,0)
;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 1-4 CKD
;;^UTILITY(U,$J,358.3,18193,1,4,0)
;;=4^I13.10
;;^UTILITY(U,$J,358.3,18193,2)
;;=^5007068
;;^UTILITY(U,$J,358.3,18194,0)
;;=I13.11^^61^806^11
;;^UTILITY(U,$J,358.3,18194,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18194,1,3,0)
;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 5 CKD/ESRD
;;^UTILITY(U,$J,358.3,18194,1,4,0)
;;=4^I13.11
;;^UTILITY(U,$J,358.3,18194,2)
;;=^5007069
;;^UTILITY(U,$J,358.3,18195,0)
;;=I13.2^^61^806^9
;;^UTILITY(U,$J,358.3,18195,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18195,1,3,0)
;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 5 CKD/ESRD
;;^UTILITY(U,$J,358.3,18195,1,4,0)
;;=4^I13.2
;;^UTILITY(U,$J,358.3,18195,2)
;;=^5007070
;;^UTILITY(U,$J,358.3,18196,0)
;;=I15.0^^61^806^15
;;^UTILITY(U,$J,358.3,18196,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18196,1,3,0)
;;=3^Renovascular Hypertension
;;^UTILITY(U,$J,358.3,18196,1,4,0)
;;=4^I15.0
;;^UTILITY(U,$J,358.3,18196,2)
;;=^5007071
;;^UTILITY(U,$J,358.3,18197,0)
;;=I15.1^^61^806^3
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI14F 3791 printed Apr 09, 2024@21:07:13 Page 2
IBDEI14F ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,18185,0)
+2 ;;=E11.620^^61^805^5
+3 ;;^UTILITY(U,$J,358.3,18185,1,0)
+4 ;;=^358.31IA^4^2
+5 ;;^UTILITY(U,$J,358.3,18185,1,3,0)
+6 ;;=3^DM Type 2 w/ Diab Dermatitis
+7 ;;^UTILITY(U,$J,358.3,18185,1,4,0)
+8 ;;=4^E11.620
+9 ;;^UTILITY(U,$J,358.3,18185,2)
+10 ;;=^5002655
+11 ;;^UTILITY(U,$J,358.3,18186,0)
+12 ;;=E11.36^^61^805^4
+13 ;;^UTILITY(U,$J,358.3,18186,1,0)
+14 ;;=^358.31IA^4^2
+15 ;;^UTILITY(U,$J,358.3,18186,1,3,0)
+16 ;;=3^DM Type 2 w/ Diab Cataract
+17 ;;^UTILITY(U,$J,358.3,18186,1,4,0)
+18 ;;=4^E11.36
+19 ;;^UTILITY(U,$J,358.3,18186,2)
+20 ;;=^5002642
+21 ;;^UTILITY(U,$J,358.3,18187,0)
+22 ;;=I10.^^61^806^1
+23 ;;^UTILITY(U,$J,358.3,18187,1,0)
+24 ;;=^358.31IA^4^2
+25 ;;^UTILITY(U,$J,358.3,18187,1,3,0)
+26 ;;=3^Essential/Primary Hypertension
+27 ;;^UTILITY(U,$J,358.3,18187,1,4,0)
+28 ;;=4^I10.
+29 ;;^UTILITY(U,$J,358.3,18187,2)
+30 ;;=^5007062
+31 ;;^UTILITY(U,$J,358.3,18188,0)
+32 ;;=I11.0^^61^806^12
+33 ;;^UTILITY(U,$J,358.3,18188,1,0)
+34 ;;=^358.31IA^4^2
+35 ;;^UTILITY(U,$J,358.3,18188,1,3,0)
+36 ;;=3^Hypertensive Heart Disease w/ Heart Failure
+37 ;;^UTILITY(U,$J,358.3,18188,1,4,0)
+38 ;;=4^I11.0
+39 ;;^UTILITY(U,$J,358.3,18188,2)
+40 ;;=^5007063
+41 ;;^UTILITY(U,$J,358.3,18189,0)
+42 ;;=I11.9^^61^806^13
+43 ;;^UTILITY(U,$J,358.3,18189,1,0)
+44 ;;=^358.31IA^4^2
+45 ;;^UTILITY(U,$J,358.3,18189,1,3,0)
+46 ;;=3^Hypertensive Heart Disease w/o Heart Failure
+47 ;;^UTILITY(U,$J,358.3,18189,1,4,0)
+48 ;;=4^I11.9
+49 ;;^UTILITY(U,$J,358.3,18189,2)
+50 ;;=^5007064
+51 ;;^UTILITY(U,$J,358.3,18190,0)
+52 ;;=I12.0^^61^806^5
+53 ;;^UTILITY(U,$J,358.3,18190,1,0)
+54 ;;=^358.31IA^4^2
+55 ;;^UTILITY(U,$J,358.3,18190,1,3,0)
+56 ;;=3^Hypertensive CKD w/ Stage 5 CKD or ESRD
+57 ;;^UTILITY(U,$J,358.3,18190,1,4,0)
+58 ;;=4^I12.0
+59 ;;^UTILITY(U,$J,358.3,18190,2)
+60 ;;=^5007065
+61 ;;^UTILITY(U,$J,358.3,18191,0)
+62 ;;=I12.9^^61^806^4
+63 ;;^UTILITY(U,$J,358.3,18191,1,0)
+64 ;;=^358.31IA^4^2
+65 ;;^UTILITY(U,$J,358.3,18191,1,3,0)
+66 ;;=3^Hypertensive CKD w/ Stage 1-4 CKD
+67 ;;^UTILITY(U,$J,358.3,18191,1,4,0)
+68 ;;=4^I12.9
+69 ;;^UTILITY(U,$J,358.3,18191,2)
+70 ;;=^5007066
+71 ;;^UTILITY(U,$J,358.3,18192,0)
+72 ;;=I13.0^^61^806^8
+73 ;;^UTILITY(U,$J,358.3,18192,1,0)
+74 ;;=^358.31IA^4^2
+75 ;;^UTILITY(U,$J,358.3,18192,1,3,0)
+76 ;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 1-4 CKD
+77 ;;^UTILITY(U,$J,358.3,18192,1,4,0)
+78 ;;=4^I13.0
+79 ;;^UTILITY(U,$J,358.3,18192,2)
+80 ;;=^5007067
+81 ;;^UTILITY(U,$J,358.3,18193,0)
+82 ;;=I13.10^^61^806^10
+83 ;;^UTILITY(U,$J,358.3,18193,1,0)
+84 ;;=^358.31IA^4^2
+85 ;;^UTILITY(U,$J,358.3,18193,1,3,0)
+86 ;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 1-4 CKD
+87 ;;^UTILITY(U,$J,358.3,18193,1,4,0)
+88 ;;=4^I13.10
+89 ;;^UTILITY(U,$J,358.3,18193,2)
+90 ;;=^5007068
+91 ;;^UTILITY(U,$J,358.3,18194,0)
+92 ;;=I13.11^^61^806^11
+93 ;;^UTILITY(U,$J,358.3,18194,1,0)
+94 ;;=^358.31IA^4^2
+95 ;;^UTILITY(U,$J,358.3,18194,1,3,0)
+96 ;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 5 CKD/ESRD
+97 ;;^UTILITY(U,$J,358.3,18194,1,4,0)
+98 ;;=4^I13.11
+99 ;;^UTILITY(U,$J,358.3,18194,2)
+100 ;;=^5007069
+101 ;;^UTILITY(U,$J,358.3,18195,0)
+102 ;;=I13.2^^61^806^9
+103 ;;^UTILITY(U,$J,358.3,18195,1,0)
+104 ;;=^358.31IA^4^2
+105 ;;^UTILITY(U,$J,358.3,18195,1,3,0)
+106 ;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 5 CKD/ESRD
+107 ;;^UTILITY(U,$J,358.3,18195,1,4,0)
+108 ;;=4^I13.2
+109 ;;^UTILITY(U,$J,358.3,18195,2)
+110 ;;=^5007070
+111 ;;^UTILITY(U,$J,358.3,18196,0)
+112 ;;=I15.0^^61^806^15
+113 ;;^UTILITY(U,$J,358.3,18196,1,0)
+114 ;;=^358.31IA^4^2
+115 ;;^UTILITY(U,$J,358.3,18196,1,3,0)
+116 ;;=3^Renovascular Hypertension
+117 ;;^UTILITY(U,$J,358.3,18196,1,4,0)
+118 ;;=4^I15.0
+119 ;;^UTILITY(U,$J,358.3,18196,2)
+120 ;;=^5007071
+121 ;;^UTILITY(U,$J,358.3,18197,0)
+122 ;;=I15.1^^61^806^3
